Carlene Lihalakha Chun, M.D., PH.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9949 S Oswego St, Parker, CO 80134 Phone: 303-925-4720 Fax: 303-925-4721 |
Lorette Johnson, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9395 Crown Crest Blvd, Parker, CO 80138 Phone: 303-643-0124 Fax: 303-629-4070 |
Thomas W Sweder, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12230 Lioness Way, Parker, CO 80134 Phone: 720-644-9355 Fax: 501-643-2785 |
Dr. Allison L Shapiro, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9395 Crown Crest Blvd, Parker, CO 80138 Phone: 303-269-4000 |
Vineela Battini, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 12230 Lioness Way, Parker, CO 80134 Phone: 720-644-9355 |
Dr. Gurvinder S Mangat, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9395 Crown Crest Blvd, Parker, CO 80138 Phone: 303-643-0124 Fax: 303-269-4070 |
Evgenia V Hanson, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9395 Crown Crest Blvd, Parker, CO 80138 Phone: 303-643-1159 Fax: 720-874-5886 |
News Archive
In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.
Older people who spent at least 14 hours a week taking care of a disabled spouse lived longer than others.
Researchers from the Johns Hopkins Kimmel Cancer Center, Indiana University and the University of Michigan have found that some women have a gene mutation that may decrease the effectiveness of tamoxifen, a commonly used breast cancer drug.
A valid and reliable tool to assess acute pain in non-communicative patients has been developed by researchers at the University of Maryland School of Nursing.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.
› Verified 9 days ago